Anders D Hove Form 3 ARCA biopharma / Anders D Hove ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Hove Anders D

(Last) (First) (Middle)

11080 CIRCLEPOINT RD., SUITE 140

(Street)

WESTMINSTER CO 80023

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/16/2017

3. Issuer Name and Ticker or Trading Symbol
ARCA biopharma, Inc. [ ABIO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	767,660	I	By Venrock Healthcare Capital Partners II, L.P.(1)
Common Stock	311,272	I	By VHCP Co-Investment Holdings II, LLC(2)
Common Stock	390,912	I	By Venrock Healthcare Capital Partners, L.P.(3)
Common Stock	71,487	I	By VHCP Co-Investment Holdings, LLC(4)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common stock warrants (right to buy)	12/13/2015	06/16/2022	Common Stock	307,064	6.1012	I	By Venrock Healthcare Capital Partners II, L.P.(1)
Common stock warrants (right to buy)	12/13/2015	06/16/2022	Common Stock	124,508	6.1012	I	By VHCP Co-Investment Holdings II, LLC(2)
Common stock warrants (right to buy)	12/13/2015	06/16/2022	Common Stock	156,365	6.1012	I	By Venrock Healthcare Capital Partners, L.P.(3)
Common stock warrants (right to buy)	12/13/2015	06/16/2022	Common Stock	28,594	6.1012	I	By VHCP Co-Investment Holdings, LLC(4)

Explanation of Responses:

1. These securities are owned directly by Venrock Healthcare Capital Partners II, L.P. The Reporting Person has a pecuniary interest in Venrock Healthcare Capital Partners II, L.P. The Reporting Person holds no voting or investment interest in these securities, and disclaims beneficial ownership of such shares except to the extent of his pro rata partnership interest therein.

2. These securities are owned directly by VHCP Co-Investment Holdings II, LLC. The Reporting Person has a pecuniary interest in VHCP Co-Investment Holdings II, LLC. The Reporting Person holds no voting or investment interest in these securities, and disclaims beneficial ownership of such shares except to the extent of his pro rata partnership interest therein.

3. These securities are owned directly by Venrock Healthcare Capital Partners, L.P. The Reporting Person has a pecuniary interest in Venrock Healthcare Capital Partners, L.P. The Reporting Person holds no voting or investment interest in these securities, and disclaims beneficial ownership of such shares except to the extent of his pro rata partnership interest therein.

4. These securities are owned directly by VHCP Co-Investment Holdings, LLC. The Reporting Person has a pecuniary interest in VHCP Co-Investment Holdings, LLC. The Reporting Person holds no voting or investment interest in these securities, and disclaims beneficial ownership of such shares except to the extent of his pro rata partnership interest therein.

Remarks:

Exhibit 24- Power of Attorney

	/s/ Brian L. Selby, Attorney-in-Fact	02/21/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.